Schizophrenia Spectrum Disorder Linked to Lower NSCLC Treatment Rates

Addressing Disparities in Cancer Care for Patients with Serious Mental Illness

Patients with schizophrenia spectrum disorders face a well-documented mortality gap, living significantly shorter lives than the general population, a disparity driven by numerous factors including higher rates of cardiovascular disease [1]. Beyond cardiovascular health, evidence points to systemic inequities in other areas of medicine, such as lower cancer screening rates [2]. While these challenges in prevention and early detection are recognized, less is known about potential disparities once a diagnosis is made. A recent large-scale study now provides specific data on treatment patterns for non-small cell lung cancer, a leading cause of cancer death [3, 4, 5]. The findings reveal that patients with schizophrenia spectrum disorders were less likely to undergo surgery (adjusted odds ratio, 0.70; 95% confidence interval, 0.57-0.85), suggesting that inequities extend deep into the course of oncologic care [6].

Investigating Treatment Gaps in Non-Small Cell Lung Cancer

Given that patients with schizophrenia spectrum disorders (SSD) have higher cancer mortality, a critical question is whether they receive the same standard of care as patients without psychiatric illness. To investigate this, a recent Japanese cohort study focused on non-small cell lung cancer (NSCLC), a condition where stage-appropriate treatment is crucial for outcomes. The researchers sought to quantify treatment disparities by posing a primary question: are patients with SSD less likely to receive surgery for NSCLC? To build a more comprehensive picture, they also examined several secondary outcomes. These included the rates of adjuvant chemotherapy for pathological stage II/IIIA disease, concurrent chemoradiotherapy for clinical stage III disease, and systemic therapy for stage IV disease. This stage-specific approach allowed the investigators to pinpoint exactly where in the treatment pathway care might diverge for this vulnerable population.

Study Design and Patient Cohort Characteristics

The investigation was designed as a retrospective cohort study, leveraging a powerful dataset from Japan's national hospital-based cancer registry linked with administrative data from 2018 to 2021. This approach allowed for a real-world analysis of treatment patterns on a large scale. The final cohort included 166,663 patients receiving initial treatment for NSCLC, of whom 1,346 had a diagnosis of SSD, as defined by the International Classification of Diseases, Tenth Revision (ICD-10) codes F20-F29. A concerning initial finding was that patients with SSD were more likely to be diagnosed at stage IV (45.0% vs. 31.4%), a disparity that suggests potential barriers to early detection or more rapid disease progression. To ensure that comparisons were fair, the researchers used multivariable logistic regression, a statistical method that isolates the effect of SSD by adjusting for key differences in age, sex, clinical stage, comorbidities, and functional status between the two groups.

Significant Disparities in NSCLC Treatment Receipt

The analysis revealed significant differences in the delivery of standard-of-care treatments for NSCLC. For the primary outcome, patients with SSD were substantially less likely to receive surgical intervention. Only 31.5% of patients with SSD underwent surgery, compared to 49.9% of those without. After statistical adjustment for clinical and demographic factors, this translated to a 30% lower likelihood of receiving surgery (adjusted odds ratio [aOR], 0.70; 95% confidence interval [CI], 0.57-0.85). The disparities extended to other stages of care. The likelihood of receiving adjuvant chemotherapy for stage II/IIIA disease was even more sharply reduced, with an aOR of 0.31 (95% CI, 0.17-0.57), indicating patients with SSD were approximately 69% less likely to receive this treatment. For patients with metastatic disease, the likelihood of receiving systemic therapy was also significantly lower, with an aOR of 0.54 (95% CI, 0.45-0.65). Interestingly, no significant difference was found for the receipt of concurrent chemoradiotherapy in stage III disease (aOR, 0.99; 95% CI, 0.73-1.34), a finding that may warrant further investigation into the specific clinical circumstances surrounding this particular treatment modality.

Clinical Implications and Future Directions

These findings from a large national cohort provide clear evidence that patients with schizophrenia spectrum disorders (SSD) receive less stage-appropriate treatment for non-small cell lung cancer (NSCLC). This undertreatment, coupled with the finding that these patients are more often diagnosed at an advanced stage, offers a direct explanation for the higher cancer mortality observed in this population. For the practicing physician, this study highlights a critical vulnerability. The data show that even after accounting for functional status and comorbidities, patients with SSD were significantly less likely to receive surgery, adjuvant chemotherapy, and systemic therapy. This suggests that factors beyond a patient's baseline health, such as communication challenges, lack of social support, or potential implicit bias, may be influencing treatment decisions. The one treatment for which parity was observed, concurrent chemoradiotherapy, is often administered in a highly structured, hospital-based setting, which may facilitate adherence for vulnerable patients. Clinicians should therefore be especially vigilant in advocating for their patients with SSD, ensuring they are referred for and receive comprehensive oncologic evaluations. Proactive coordination between psychiatric and oncology teams is essential to navigate the complexities of cancer care for these individuals. Ultimately, this research calls for the development of integrated care models to bridge the gap between mental and physical health, ensuring that a diagnosis of serious mental illness does not preclude access to life-saving cancer treatment.

References

1. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions. Frontiers in Psychiatry. 2014. doi:10.3389/fpsyt.2014.00137

2. Solmi M, Firth J, Miola A, et al. Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people. The Lancet Psychiatry. 2019. doi:10.1016/s2215-0366(19)30414-6

3. Ferrari AJ, Santomauro D, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024. doi:10.1016/s0140-6736(24)00757-8

4. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017. doi:10.1016/s0140-6736(17)32154-2

5. Vos T, Allen CA, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016. doi:10.1016/s0140-6736(16)31678-6

6. Yamada Y, Fujiwara M, Ishii T, et al. Impact of pre-existing schizophrenia spectrum disorder on the receipt of surgery and other treatments for non-small cell lung cancer: A multicenter nationwide cohort study in Japan.. Chest. 2026. doi:10.1016/j.chest.2026.05.016